A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody, in advanced cancers.

@inproceedings{Papadopoulos2018ASO,
  title={A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody, in advanced cancers.},
  author={Kyriakos P Papadopoulos and Nehal J. Lakhani and Melissa Lynne Johnson and Haeseong Park and Ding Wang and Timothy A Yap and Kathleen N. Moore and Tasha Nicholle Sims and Chetachi Akunna Emeremni and Maria Karasarides and Glenn Scott Kroog},
  year={2018}
}
TPS3127Background: Lymphocyte activation gene 3 (LAG-3) is an immune checkpoint receptor with a biological role in T cell regulation. Analysis of immune-cell infiltrates from human tumors show that... 

Similar Papers

Topics from this paper.

Citations

Publications citing this paper.

Cemiplimab: First Global Approval

VIEW 1 EXCERPT
CITES BACKGROUND